Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI
Several respiratory pathogens are responsible for influenza-like illness (ILI) and severe respiratory infections (SARI), among which human respiratory syncytial virus (hRSV) represents one of the most common aetiologies. We analysed the hRSV prevalence among subjects with ILI or SARI during the five...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/11/1334 |
| _version_ | 1797508316844261376 |
|---|---|
| author | Fabio Tramuto Carmelo Massimo Maida Daniela Di Naro Giulia Randazzo Francesco Vitale Vincenzo Restivo Claudio Costantino Emanuele Amodio Alessandra Casuccio Giorgio Graziano Palmira Immordino Walter Mazzucco |
| author_facet | Fabio Tramuto Carmelo Massimo Maida Daniela Di Naro Giulia Randazzo Francesco Vitale Vincenzo Restivo Claudio Costantino Emanuele Amodio Alessandra Casuccio Giorgio Graziano Palmira Immordino Walter Mazzucco |
| author_sort | Fabio Tramuto |
| collection | DOAJ |
| description | Several respiratory pathogens are responsible for influenza-like illness (ILI) and severe respiratory infections (SARI), among which human respiratory syncytial virus (hRSV) represents one of the most common aetiologies. We analysed the hRSV prevalence among subjects with ILI or SARI during the five influenza seasons before the emergence of SARS-CoV-2 epidemic in Sicily (Italy). Respiratory specimens from ILI outpatients and SARI inpatients were collected in the framework of the Italian Network for the Influenza Surveillance and molecularly tested for hRSV-A and hRSV-B. Overall, 8.1% of patients resulted positive for hRSV. Prevalence peaked in the age-groups <5 years old (range: 17.6–19.1%) and ≥50 years old (range: 4.8–5.1%). While the two subgroups co-circulated throughout the study period, hRSV-B was slightly predominant over hRSV-A, except for the season 2019–2020 when hRSV-A strongly prevailed (82.9%). In the community setting, the distribution of hRSV subgroups was balanced (47.8% vs. 49.7% for hRSV-A and hRSV-B, respectively), while most infections identified in the hospital setting were caused by hRSV-B (69.5%); also, this latter one was more represented among hRSV cases with underlying diseases, as well as among those who developed a respiratory complication. The molecular surveillance of hRSV infections may provide a valuable insight into the epidemiological features of ILI/SARI. Our findings add new evidence to the existing knowledge on viral aetiology of ILI and SARI in support of public health strategies and may help to define high-risk categories that could benefit from currently available and future vaccines. |
| first_indexed | 2024-03-10T05:00:22Z |
| format | Article |
| id | doaj.art-9f50be60d8b54e82a07aa68c4b3dd611 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T05:00:22Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-9f50be60d8b54e82a07aa68c4b3dd6112023-11-23T01:53:17ZengMDPI AGVaccines2076-393X2021-11-01911133410.3390/vaccines9111334Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARIFabio Tramuto0Carmelo Massimo Maida1Daniela Di Naro2Giulia Randazzo3Francesco Vitale4Vincenzo Restivo5Claudio Costantino6Emanuele Amodio7Alessandra Casuccio8Giorgio Graziano9Palmira Immordino10Walter Mazzucco11Department of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties “G. D’Alessandro”–Hygiene Section, University of Palermo, 90127 Palermo, ItalyDepartment of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties “G. D’Alessandro”–Hygiene Section, University of Palermo, 90127 Palermo, ItalyRegional Reference Laboratory for Molecular Surveillance of Influenza, Clinical Epidemiology Unit, University Hospital “Paolo Giaccone”, 90127 Palermo, ItalyRegional Reference Laboratory for Molecular Surveillance of Influenza, Clinical Epidemiology Unit, University Hospital “Paolo Giaccone”, 90127 Palermo, ItalyDepartment of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties “G. D’Alessandro”–Hygiene Section, University of Palermo, 90127 Palermo, ItalyDepartment of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties “G. D’Alessandro”–Hygiene Section, University of Palermo, 90127 Palermo, ItalyDepartment of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties “G. D’Alessandro”–Hygiene Section, University of Palermo, 90127 Palermo, ItalyDepartment of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties “G. D’Alessandro”–Hygiene Section, University of Palermo, 90127 Palermo, ItalyDepartment of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties “G. D’Alessandro”–Hygiene Section, University of Palermo, 90127 Palermo, ItalyRegional Reference Laboratory for Molecular Surveillance of Influenza, Clinical Epidemiology Unit, University Hospital “Paolo Giaccone”, 90127 Palermo, ItalyDepartment of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties “G. D’Alessandro”–Hygiene Section, University of Palermo, 90127 Palermo, ItalyDepartment of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties “G. D’Alessandro”–Hygiene Section, University of Palermo, 90127 Palermo, ItalySeveral respiratory pathogens are responsible for influenza-like illness (ILI) and severe respiratory infections (SARI), among which human respiratory syncytial virus (hRSV) represents one of the most common aetiologies. We analysed the hRSV prevalence among subjects with ILI or SARI during the five influenza seasons before the emergence of SARS-CoV-2 epidemic in Sicily (Italy). Respiratory specimens from ILI outpatients and SARI inpatients were collected in the framework of the Italian Network for the Influenza Surveillance and molecularly tested for hRSV-A and hRSV-B. Overall, 8.1% of patients resulted positive for hRSV. Prevalence peaked in the age-groups <5 years old (range: 17.6–19.1%) and ≥50 years old (range: 4.8–5.1%). While the two subgroups co-circulated throughout the study period, hRSV-B was slightly predominant over hRSV-A, except for the season 2019–2020 when hRSV-A strongly prevailed (82.9%). In the community setting, the distribution of hRSV subgroups was balanced (47.8% vs. 49.7% for hRSV-A and hRSV-B, respectively), while most infections identified in the hospital setting were caused by hRSV-B (69.5%); also, this latter one was more represented among hRSV cases with underlying diseases, as well as among those who developed a respiratory complication. The molecular surveillance of hRSV infections may provide a valuable insight into the epidemiological features of ILI/SARI. Our findings add new evidence to the existing knowledge on viral aetiology of ILI and SARI in support of public health strategies and may help to define high-risk categories that could benefit from currently available and future vaccines.https://www.mdpi.com/2076-393X/9/11/1334respiratory syncytial virusmolecular surveillancerisk factorsvaccinationcommunityhospitalization |
| spellingShingle | Fabio Tramuto Carmelo Massimo Maida Daniela Di Naro Giulia Randazzo Francesco Vitale Vincenzo Restivo Claudio Costantino Emanuele Amodio Alessandra Casuccio Giorgio Graziano Palmira Immordino Walter Mazzucco Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI Vaccines respiratory syncytial virus molecular surveillance risk factors vaccination community hospitalization |
| title | Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI |
| title_full | Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI |
| title_fullStr | Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI |
| title_full_unstemmed | Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI |
| title_short | Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI |
| title_sort | respiratory syncytial virus new challenges for molecular epidemiology surveillance and vaccination strategy in patients with ili sari |
| topic | respiratory syncytial virus molecular surveillance risk factors vaccination community hospitalization |
| url | https://www.mdpi.com/2076-393X/9/11/1334 |
| work_keys_str_mv | AT fabiotramuto respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT carmelomassimomaida respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT danieladinaro respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT giuliarandazzo respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT francescovitale respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT vincenzorestivo respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT claudiocostantino respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT emanueleamodio respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT alessandracasuccio respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT giorgiograziano respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT palmiraimmordino respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT waltermazzucco respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari |